C. Boucher

B. Alisjahbana, C. Boucher, M. Schutten, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Ongoing HIV Replication in Cerebrospinal Fluid under Successful Monotherapy

C. Boucher, R. W. Kate, A. Fibriani, 2013, Antiviral therapy.

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey

Thomas Lengauer, R. Kaiser, A. Vandamme, 2019, PloS one.

Classes of Antiviral Drugs

C. Boucher, M. Westreenen, 2002 .

Low cost HIV-1 quantitative RT-PCR assay in resource-limited settings: improvement and implementation.

C. Boucher, M. Schutten, R. van Crevel, 2012, Journal of virological methods.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

C. Boucher, W. Bierman, S. Danner, 2009, AIDS.

Reverse transcriptase fidelity and HIV-1 variation.

B. Berkhout, C. Boucher, W. Keulen, 1997, Science.

Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010.

A. Osterhaus, C. Boucher, M. Koopmans, 2011, Antiviral research.

Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses.

J. Mossong, U. Buchholz, S. Buda, 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.

A. Wensing, C. Boucher, C. Richter, 2001, AIDS.

Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic stem cell transplantation

C. Boucher, B. van der Holt, J. Gratama, 2001, British journal of haematology.

Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008

F. Schellevis, A. Osterhaus, C. Boucher, 2011, The open virology journal.

Consensus symposium on combined antiviral therapy

M. Hirsch, D. Richman, C. Boucher, 1996 .

Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy

C. Boucher, W. Bierman, M. V. van Kasteren, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

No HIV infections despite high numbers of hepatitis B and C virus infections in Dutch prisoners

A. Osterhaus, C. Boucher, C. Hoebe, 2011 .

Second European Round Table on the Future Management of HIV

M. Altfeld, D. Richman, B. Clotet, 2015, Journal of virus eradication.

Zidovudine plus interferon-α versus zidovudine alone in HIV‐infected symptomatic or asymptomatic persons with CD4+ cell counts > 150x106/l: results of the Zidon trial

C. Boucher, P. Dowd, J. Lang, 1995 .

Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.

C. Boucher, P. Dowd, J. Lang, 1995, AIDS.

Summary of the III International Consensus Symposium on Combined Antiviral Therapy.

D. Richman, H. Thomas, D. Cooper, 1998, Antiviral research.

Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase

B. Berkhout, C. Boucher, A. V. van Wijk, 1997, Journal of virology.

Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

W. Keulen, B. Berkhout, C. Boucher, 1996, The EMBO journal.

Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies

D. Richman, B. Gazzard, J. Montaner, 1997, Antiviral Research.

Leflunomide as part of the treatment for multidrug‐resistant cytomegalovirus disease after lung transplantation: case report and review of the literature

H. Hoogsteden, C. Boucher, R. Hoek, 2013, Transplant infectious disease : an official journal of the Transplantation Society.

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

M. Wainberg, C. Boucher, P. Schipper, 1993, Antimicrobial Agents and Chemotherapy.

The global spread of HIV-1 subtype B epidemic

M. Poljak, A. Wensing, R. Paredes, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Practical guidelines in antiviral therapy

D. Katzenstein, D. Cooper, C. Boucher, 2002 .

No predictive value of GC phenotypes for HIV infection and progression to AIDS

C. Boucher, R. Frants, A. Eriksson, 1988, Human Genetics.

Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections.

D. Richman, B. Gazzard, C. Katlama, 1998, Antiviral research.

Molecular Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors

C. Boucher, M. Huigen, 2009 .

Broad Advances in Understanding HIV Resistance to Antiretrovirals: Report on the XVII International HIV Drug Resistance Workshop

D. Richman, B. Larder, J. Mellors, 2008, Antiviral therapy.

Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.

C. Boucher, H. Janssen, B. Hansen, 2011, The Journal of infectious diseases.

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

J. Schapiro, C. Boucher, R. Aarnoutse, 2003, Drugs.

Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase

C. Boucher, P. Reichelderfer, R. Schuurman, 1999, Journal of Clinical Microbiology.

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

M. Wainberg, Q. Gao, C. Boucher, 1993, Antimicrobial Agents and Chemotherapy.

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine

A. Perelson, C. Boucher, R. D. de Boer, 1998, AIDS.

Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels

K. Simon, C. Boucher, U. Akarca, 2010, Hepatology.

Effect of Weekly Adefovir (PMEA) Infusions on HIV-1 Virus Load: Results of a Phase I/II Study

C. Boucher, R. Schuurman, T. de Groot, 1998, Antiviral therapy.

Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.

C. Boucher, N. V. van Maarseveen, M. Nijhuis, 2009, Handbook of experimental pharmacology.

The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count)

C. Boucher, A. Hoepelman, A. Weersink, 2003, AIDS.

A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.

C. Boucher, H. Janssen, B. Hansen, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity.

C. Boucher, M. Huigen, D. Eggink, 2007, Antiviral research.

Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.

P. Reiss, C. Boucher, S. Danner, 1997, Antiviral Therapy.

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

B. Larder, C. Boucher, P. Kellam, 1990, The Lancet.

Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.

J. Schapiro, C. Flexner, T. Blaschke, 2006 .

Therapeutic Drug Monitoring

J. Schapiro, C. Boucher, R. Aarnoutse, 2012, Drugs.

Vertical HIV-1 transmission correlates with a high maternal viral load at delivery.

C. Boucher, I. Caragol, O. Coll, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues

E. De Clercq, C. Pannecouque, B. Clotet, 2000, Antimicrobial Agents and Chemotherapy.

The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2006, Journal of acquired immune deficiency syndromes.

Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

B. Larder, C. Boucher, P. Kellam, 1994, The Journal of general virology.

Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy

C. Boucher, R. Schuurman, A. Hoepelman, 2009, Journal of medical virology.

Mixed infections of pandemic H1N1 and seasonal H3N2 viruses in 1 outbreak.

W. Liu, Hong Yang, Y. Tong, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir

J. Leonard, A. Molla, C. Boucher, 1998, AIDS.

Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world.

C. Boucher, D. A. van de Vijver, D. Frentz, 2012, AIDS reviews.

High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.

M. Moroni, D. Cooper, P. Reiss, 1997, The Journal of infectious diseases.

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.

C. Boucher, H. Janssen, B. Hansen, 2011, Journal of hepatology.

An automated genotyping system for analysis of HIV-1 and other microbial sequences

Tulio de Oliveira, Christopher J. Seebregts, David A. van de Vijver, 2005, Bioinform..

The Dominant Source of CD4+ and CD8+ T‐Cell Activation in HIV Infection Is Antigenic Stimulation

C. Boucher, R. D. de Boer, S. Otto, 2000, Journal of acquired immune deficiency syndromes.

Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.

Diana D. Huang, C. Boucher, J. Bremer, 2002, AIDS research and human retroviruses.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.

A. Wensing, C. Boucher, A. van Laarhoven, 2015, The Journal of antimicrobial chemotherapy.

[Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].

C. Boucher, A. Weersink, I. Hoepelman, 2004, Nederlands tijdschrift voor geneeskunde.

Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial.

C. Boucher, 2001, Archives of disease in childhood.

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.

Tom de Groot, C. Boucher, S. Danner, 1997, The Journal of infectious diseases.

State of the antiretroviral therapy in human immunodeficiency virus drug resistance

R. Kaiser, A. Vandamme, C. Boucher, 2018 .

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

Jan Albert, Kirsi Liitsola, Mario Poljak, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia.

M. Poljak, A. Wensing, R. Paredes, 2015, The Journal of infectious diseases.

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients

C. Boucher, R. D. de Knegt, H. Janssen, 2017, Scientific Reports.

A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants.

C. Boucher, M. Huigen, N. V. van Maarseveen, 2006, Journal of virological methods.

Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.

B. Berkhout, C. Boucher, R. Sanders, 2001, Virology.

A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism

Eoin Coakley, Monique Nijhuis, Colombe Chappey, 2007, PLoS medicine.

Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir

Jonathan M. Schapiro, J. Schapiro, C. Boucher, 2006, Journal of Virology.

A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection

J. R. Contreras, S. Polywka, S. Hannam, 2005 .

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients

D. Cooper, C. Boucher, A. Imrie, 1996, AIDS.

Implications of antiretroviral resistance on viral fitness

C. Boucher, S. Deeks, M. Nijhuis, 2001, Current opinion in infectious diseases.

Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase

C. Boucher, R. Kagan, M. Huigen, 2008, Retrovirology.

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

C. Boucher, B. Bravenboer, C. Richter, 1999, AIDS.

Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance

Steve Kaye, Annemarie M. J. Wensing, Rob Schuurman, 2001, Journal of acquired immune deficiency syndromes.

Overshoot of HIV‐1 viraemia after early discontinuation of antiretroviral treatment

C. Boucher, R. D. de Boer, N. Foudraine, 1997, AIDS.

Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis.

H. Schuitemaker, C. Boucher, A. B. van 't Wout, 1996, The Journal of infectious diseases.

Hepatitis C virus and human immunodeficiency virus coinfection: where do we stand?

C. Boucher, A. Hoepelman, A. Hoepelman, 2005, The Netherlands journal of medicine.

H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis

P. Collins, J. Skehel, X. Xiong, 2012, PLoS pathogens.

H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis

P. Collins, J. Skehel, X. Xiong, 2012, PLoS pathogens.

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

M. M. van der Eerden, C. Boucher, M. Koopmans, 2021, Nature communications.

An Increase in Viral Replicative Capacity Drives the Evolution of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Drugs

C. Boucher, N. V. van Maarseveen, M. Nijhuis, 2006, Journal of acquired immune deficiency syndromes.

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.

Eleni-Rosalina Andrinopoulou, Bart Rijnders, E. Andrinopoulou, 2017, The lancet. HIV.

Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma

F. Brun-Vézinet, I. Williams, C. Loveday, 1996, Journal of clinical microbiology.

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

C. Boucher, R. D. de Boer, N. Stilianakis, 1996, Proceedings of the National Academy of Sciences of the United States of America.

T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).

F Miedema, F. Miedema, C. Boucher, 2000, Blood.

Reply to Darcis and Berkhout.

C. Boucher, H. Pham, D. A. van de Vijver, 2018, The Journal of infectious diseases.

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

C. Boucher, H. Pham, D. A. van de Vijver, 2018, The Journal of infectious diseases.

Chapter 3 HIV-1 resistance dynamics in patients with virological failure to dolutegravir maintenance monotherapy .

C. Boucher, R. Schuurman, T. Mesplède, 2018 .

Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection

Rob J. de Boer, Charles A. Boucher, C. Boucher, 2000, Nature Medicine.

Aciclovir for dual infection with HIV and HSV.

C. Boucher, G. Verjans, 2012, The Lancet. Infectious diseases.

Improving the Prediction of Virological Response to Tipranavir: The Development and Validation of a Tipranavir-Weighted Mutation Score

J. Schapiro, C. Boucher, C. Perno, 2010, Antiviral therapy.

Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients

H. Hoogsteden, M. M. van der Eerden, C. Boucher, 2013, Scandinavian journal of infectious diseases.

Strengthening the diagnostic capacity to detect Bio Safety Level 3 organisms in unusual respiratory viral outbreaks.

C. Boucher, M. Koopmans, W. Melchers, 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Transmission of drug-resistance in Europe is characterized by single mutations and revertants

A. Wensing, K. Korn, G. Poggensee, 2006 .

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2005, The Journal of infectious diseases.

Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection.

C. Boucher, M. Visser, J. Verhoef, 1998, The Journal of infectious diseases.

Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.

P. Reiss, C. Boucher, G. Weverling, 1998, AIDS research and human retroviruses.

Transmission of NS5A-Inhibitor Resistance-Associated Substitutions Among Men Who Have Sex With Men Recently Infected with Hepatitis C Virus Genotype 1a

C. Boucher, A. Dofferhof, W. Bierman, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multidrug Resistant 2009 A/H1N1 Influenza Clinical Isolate with a Neuraminidase I223R Mutation Retains Its Virulence and Transmissibility in Ferrets

Erhard van der Vries, Martin Linster, Albert D. M. E. Osterhaus, 2011, PLoS pathogens.

Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase

A. Osterhaus, C. Boucher, M. Koopmans, 2009, Journal of Clinical Virology.

Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection

S. Frost, C. Boucher, M. Nijhuis, 2000, Journal of Virology.

Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach

O. Pybus, A. Wensing, K. Korn, 2009, Retrovirology.

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

Anne-Mieke Vandamme, Soo-Yon Rhee, Tommy F. Liu, 2009, PloS one.

Transmission of drug-resistant HIV-1 is stabilizing in Europe.

M. Poljak, A. Wensing, K. Korn, 2009, The Journal of infectious diseases.

Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity

M. Poljak, A. Wensing, C. Boucher, 2014, Retrovirology.

Evolutionary pathways of transmitted drug-resistant HIV-1.

A. Wensing, C. Boucher, M. Nijhuis, 2011, The Journal of antimicrobial chemotherapy.

Key Reports from the XV International HIV Drug Resistance Workshop 2006

D. Richman, B. Larder, J. Mellors, 2007, Antiviral therapy.

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Klaus Korn, Kristof Theys, Anne-Mieke Vandamme, 2013, Retrovirology.

Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group

M. Poljak, R. Paredes, K. Korn, 2014, PloS one.

Development of C-TILDA: a modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1.

T. Mahmoudi, C. Boucher, L. Calza, 2019, Journal of virological methods.

Worldwide transmission of drug-resistant HIV.

A. Wensing, C. Boucher, 2003, AIDS reviews.

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

Lidia Ruiz, Bonaventura Clotet, B. Clotet, 2002, AIDS.

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting

K. Hertogs, F. Brun-Vézinet, D. Pillay, 2001 .

Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS Medicine.

Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.

C. Boucher, L. Epstein, L. van der Hoek, 1988, AIDS.

Acute hepatitis C virus infection.

C. Boucher, W. Irving, D. Salmon, 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand

A. Trkola, P. Tovey, C. Königs, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Title: Induction of selective cell death in HIV-1-infected cells by DDX3

T. Mahmoudi, C. Boucher, Robert-Jan Palstra, 2020 .

The Epidemiology of Transmission of Drug Resistant HIV-1

Annemarie M. J. Wensing, A. Wensing, C. Boucher, 2007 .

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal

T. Mahmoudi, C. Boucher, Robert-Jan Palstra, 2015, EBioMedicine.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

Securing sustainable funding for viral hepatitis elimination plans

G. Papandreou, M. Manns, J. Lazarus, 2019, Liver international : official journal of the International Association for the Study of the Liver.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors

M. Wainberg, B. Brenner, C. Boucher, 2018, The Journal of infectious diseases.

High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands

B. Berkhout, M. Wegdam, R. Meijering, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

B. Larder, C. Boucher, P. Kellam, 1992, The Journal of infectious diseases.

Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model

C. Boucher, R. D. de Boer, N. Stilianakis, 1997, Journal of virology.

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

C. Boucher, S. Gulnik, J. Erickson, 1999, AIDS.

High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.

T. van der Poll, M. V. van Zelm, R. Koup, 2019, Journal of hepatology.

Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.

C. Boucher, M. D. de Jong, R. Schuurman, 1996, Antiviral therapy.

Efficacy of the Latest Generation of Antibody Assays for (Early) Detection of HIV 1 and HIV 2 Infection

C. Boucher, H. Reesink, J. Goudsmit, 1989, Vox sanguinis.

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C

F. Ceccherini‐Silberstein, C. Boucher, S. Popping, 2018, Journal of virus eradication.

Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.

C. Debouck, P. Reiss, C. Kuiken, 1991, Journal of acquired immune deficiency syndromes.

Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction.

C. Boucher, M. Nijhuis, R. Schuurman, 1995, BioTechniques.

Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA

T. Mahmoudi, G. Pantaleo, C. Boucher, 2020, Viruses.

Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model

A. Wensing, C. Boucher, T. Geijtenbeek, 2014, Retrovirology.

Identifying potential survival strategies of HIV-1 through virus-host protein interaction networks

Peter M. A. Sloot, David van Dijk, Gökhan Ertaylan, 2010, BMC Systems Biology.

Influenza virus resistance to antiviral therapy.

A. Osterhaus, C. Boucher, E. van der Vries, 2013, Advances in pharmacology.

Anti-CD4 therapy for AIDS suggested by mathematical models

C. Boucher, R. D. de Boer, R J De Boer, 1996, Proceedings of the Royal Society of London. Series B: Biological Sciences.

Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses

P. Coveney, C. Charpentier, C. Boucher, 2014, Journal of Virology.

How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact

T. Hallett, D. Pillay, J. Mellors, 2016, PloS one.

Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058

C. Boucher, C. Spinner, C. Kollan, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study

R. Baltussen, J. H. van de Wijgert, P. Sloot, 2013, PloS one.

Unite forces to validate biomarkers in the quest for lasting HIV remission.

C. Boucher, Y. Lévy, S. Vella, 2016, AIDS.

Antibody response to human immunodeficiency virus type 1 protease according to risk group and disease stage

C. Debouck, C. Boucher, L. Epstein, 1989, Journal of clinical microbiology.

Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings.

C. Boucher, B. Nichols, L. Long, 2020, The lancet. HIV.

Cost-Effectiveness of PrEP in HIV/AIDS Control in Zambia: A Stochastic League Approach

R. Baltussen, C. Boucher, J. Nouwen, 2014, Journal of acquired immune deficiency syndromes.

Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study

C. Boucher, B. Nichols, D. A. van de Vijver, 2015, PloS one.

Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs

C. Boucher, D. A. van de Vijver, D. Paraskevis, 2020, Viruses.

Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis.

C. Kuiken, C. Boucher, J. Goudsmit, 1993, AIDS.

Primary resistance to integrase strand-transfer inhibitors in Europe.

M. Poljak, R. Paredes, C. Boucher, 2015, The Journal of antimicrobial chemotherapy.

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.

C. Boucher, A. V. van Wijk, M. Nijhuis, 2000, AIDS.

[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].

C. Boucher, E. O. D. Op de Coul, M. V. van Agtmael, 2013, Nederlands tijdschrift voor geneeskunde.

Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.

C. Boucher, J. Drenth, R. D. de Knegt, 2013, The Netherlands journal of medicine.

Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance

C. Boucher, A. Sönnerborg, D. A. van de Vijver, 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Evolution of a novel 5-amino-acid insertion in the β3-β4 loop of HIV-1 reverse transcriptase

D. Stammers, C. Boucher, M. Huigen, 2007 .

Implications of HIV Drug Resistance on First- and Second-Line Therapies in Resource-Limited Settings: Report from a Workshop Organized by the Collaborative HIV and Anti-HIV Drug Resistance Network

F. Brun-Vézinet, B. Clotet, D. Pillay, 2013, Antiviral therapy.

Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses

P. Coveney, C. Charpentier, C. Boucher, 2014, Journal of Virology.

Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates

B. Larder, C. Boucher, P. Kellam, 1993, Antimicrobial Agents and Chemotherapy.

Novel mechanisms of HIV protease inhibitor resistance

C. Boucher, N. V. van Maarseveen, M. Nijhuis, 2008, Current opinion in HIV and AIDS.

Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity

C. Boucher, P. Schipper, D. Andersson, 2012, Retrovirology.

Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

Monique Nijhuis, A. Wensing, C. Boucher, 2009, The Journal of infectious diseases.

Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region

Monique Nijhuis, Ron M. Kagan, Charles A. Boucher, 2008, Journal of Virology.

HIV protease resistance and viral fitness

C. Boucher, N. V. van Maarseveen, M. Nijhuis, 2007, Current Opinion in HIV and AIDS.

Resistance to protease inhibitors

C. Boucher, N. V. Maarseveen, 2006 .

Two highly antigenic sites in the human immunodeficiency virus type 1 reverse transcriptase

C. Boucher, F. Chiodi, E. Norrby, 1993, Journal of clinical microbiology.

The potential for multidrug-resistant influenza

C. Boucher, E. van der Vries, M. Schutten, 2011, Current opinion in infectious diseases.

Transmission networks of HIV-1 among men having sex with men in the Netherlands

Ard van Sighem, Frank de Wolf, Daniela Bezemer, 2010, AIDS.

Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe.

C. Boucher, D. A. van de Vijver, I. Derdelinckx, 2009, The Journal of infectious diseases.

Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.

B. Cowling, X. Tong, C. Boucher, 2016, The Journal of infectious diseases.

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

M. Poljak, A. Wensing, R. Paredes, 2014, BMC Infectious Diseases.

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma.

C. Boucher, R. de Wit, P. Bakker, 1988, Lancet.

Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching

R. Shafer, B. Clotet, J. Schapiro, 2008, AIDS.

Ending AIDS as a Public Health Threat by 2030: Scientific Developments from the 2016 Interest Conference in Yaoundé, Cameroon

C. Boucher, G. Ferrari, E. Katabira, 2017, Antiviral therapy.

CHAPTER 62 – Surveillance of Antiretroviral Drug Resistance in Resource-poor Settings

C. Boucher, I. Derdelinckx, 2008 .

Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice.

C. Boucher, P. Schipper, A. V. van Loon, 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients

D. Kuritzkes, J. Schapiro, C. Boucher, 2011, Antiviral therapy.

Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time

Peter M. A. Sloot, Matthias Assel, Anne-Mieke Vandamme, 2010, PloS one.

Serum reactivity to HIV-1 accessory gene products distinguishes East African from West African HIV strains as infecting agent.

C. Debouck, C. Boucher, J. Goudsmit, 1989, AIDS research and human retroviruses.

Case report: Oseltamivir‐induced resistant pandemic influenza A (H1N1) Virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia

C. Boucher, J. V. van Kampen, J. Maaskant, 2013, Journal of medical virology.

Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.

A. Wensing, C. Boucher, N. V. van Maarseveen, 2007, The Journal of infectious diseases.

Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection

M. Wainberg, C. Boucher, A. Hill, 2006, PLoS medicine.

First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands.

C. Boucher, J. Goudsmit, R. Schuurman, 1996, AIDS.

RegaDB: community-driven data management and analysis for infectious diseases

Jean Ruelle, Peter M. A. Sloot, Stefan Wesner, 2013, Bioinform..

Extracting causal relations on HIV drug resistance from literature

Quoc-Chinh Bui, Breanndán Ó Nualláin, Charles A Boucher, 2010, BMC Bioinformatics.

The xenotropic murine leukemia virus-related retrovirus debate continues at first international workshop

R. Silverman, C. Boucher, S. L. Le Grice, 2010, Retrovirology.

Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.

A. Wensing, R. Paredes, R. Kaiser, 2015, The Journal of antimicrobial chemotherapy.

Virological failure and drug resistance during first line anti‐retroviral treatment in Indonesia

B. Alisjahbana, C. Boucher, M. Schutten, 2013, Journal of medical virology.

Cellular Automata Model of Drug Therapy for HIV Infection

Peter M. A. Sloot, Fan Chen, Charles A. Boucher, 2002, ACRI.

Initial appearance of the 184 I 1 e variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase

B. Berkhout, C. Boucher, Albert, 1997 .

Initial appearance of the 184I1e variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase

B. Berkhout, C. Boucher, Albert, 1997 .

Limited cross-border infections in patients newly diagnosed with HIV in Europe

M. Poljak, A. Wensing, R. Paredes, 2013, Retrovirology.

Alternation of Antiretroviral Drug Regimens for HIV Infection

Lidia Ruiz, Kurt Hertogs, Ayumi Shintani, 2003, Annals of Internal Medicine.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance

Jerome H. Kim, M. Poljak, R. Shafer, 2015 .

Antibody response to a synthetic peptide covering a LAV-1/HTLV-IIIB neutralization epitope and disease progression.

C. Boucher, J. Goudsmit, F. de Wolf, 1989, AIDS.

Immune response and epitope mapping of a candidate hiv‐1 p17 vaccine hgp30

C. Boucher, R. Meloen, A. Goldstein, 1990, Journal of clinical laboratory analysis.

Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase.

D. Stammers, C. Boucher, M. Huigen, 2007, Virology.

HIV-1 Can Persist in Aged Memory CD4+ T Lymphocytes With Minimal Signs of Evolution After 8.3 Years of Effective Highly Active Antiretroviral Therapy

D. Baarle, C. Boucher, N. Vrisekoop, 2009, Journal of acquired immune deficiency syndromes.

Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.

B. Berkhout, C. Boucher, A. V. van Wijk, 1999, AIDS.

Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré Syndrome

C. Boucher, J. Gans, R. Oers, 1988, Clinical Neurology and Neurosurgery.

HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies

D. Richman, B. Larder, J. Mellors, 2011, Antiviral therapy.

HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier.

J. Beijnen, C. Boucher, P. Portegies, 1997, Antiviral Therapy.

How testing for HIV resistance influences therapeutic decision making. Analysis of a sample of 600 clinicians.

A. Wensing, C. Boucher, M. Mascolini, 2001, IAPAC monthly.

Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins.

B. Berkhout, C. Boucher, W. Keulen, 1996, Antiviral research.

Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

C. Tinelli, C. Boucher, S. Lo Caputo, 2003, The Journal of infectious diseases.

Stochastic Modeling of Temporal Variability of HIV-1 Population

Peter M. A. Sloot, Alexander Boukhanovsky, Charles A. Boucher, 2003, International Conference on Computational Science.

HIV resistance assay results and their effect on therapeutic decisions.

A. Wensing, C. Boucher, M. Mascolini, 2001, AIDS.

Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity

C. Boucher, P. Schipper, D. Andersson, 2012, Retrovirology.

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency

R. Kaiser, C. Boucher, V. Dalm, 2019, Open forum infectious diseases.

Clinical experience with non-nucleoside reverse transcriptase inhibitors.

J. Phair, S. Staszewski, C. Boucher, 1997, AIDS.

Chapter 2 Dolutegravir as maintenance monotherapy for HIV ( DOMONO ) : a phase 2 , randomised non-inferiority trial

C. Boucher, W. Bierman, H. Bax, 2018 .

Phase I/II study of 3TC (lamivudine) in HIV‐positive, asymptomatic or mild AIDS‐related complex patients: sustained reduction in viral markers

C. Robert, C. Loveday, C. Boucher, 1995 .

Clinical Implications of Resistance to Antiretrovirals: New Resistance Technologies and Interpretations

D. Richman, B. Larder, J. Mellors, 2008, Antiviral therapy.

Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.

B. Clotet, J. Martinez-Picado, L. Ruiz, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression.

C. Boucher, L. Epstein, E. Connor, 1988, Pediatrics.

HOMOLOGOUS RECOMBINATION FOR RAPID PHENOTYPING OF HIV

C. Boucher, M. Nijhuis, R. Schuurman, 1997 .

Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus.

H. Schuitemaker, C. Boucher, J. Veenstra, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Journal of Computer Mathematics Stochastic Simulation of Hiv Population Dynamics through Complex Network Modelling Stochastic Simulation of Hiv Population Dynamics through Complex Network Modelling

Peter M. A. Sloot, David A. van de Vijver, Alexander Boukhanovsky, 2022 .

Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms.

C. Boucher, J. Albert, D. A. van de Vijver, 2011, Journal of acquired immune deficiency syndromes.

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.

Abdel Babiker, Philippe Flandre, Peter Reiss, 1999, AIDS.